Mr. James Yamanaka reports

ORGANIGRAM ANNOUNCES PROPOSED ACQUISITION OF SANITY GROUP, A LEADING GERMAN CANNABIS COMPANY

Organigram Global Inc. has entered into a definitive agreement to acquire all the issued and outstanding shares of Sanity Group GmbH not currently owned by Organigram.

Upon closing of the acquisition, Organigram will pay shareholders of Sanity (collectively, the vendors) upfront consideration of 113.4 million euros consisting of 80.0 million euros cash and share consideration of 33.4 million euros in Organigram shares. In addition, the vendors will be entitled to receive consideration of up to 113.8 million euros, with the first 20 million euros in cash and up to 93.8 million euros in Organigram shares (earnout consideration) based on Sanity's financial performance for the 12-month period following the closing. The upfront consideration shares are expected to be priced at $3.00 per Organigram share, representing a 71-per-cent premium to the $1.75 closing price on the Toronto Stock Exchange (TSX) on Feb. 17, 2026. The earnout consideration shares shall be priced at the TSX 20-day VWAP (volume-weighted average price) on the trading day prior to settlement, subject to a $3.00 floor and $4.00 cap.

"The proposed acquisition of Sanity Group marks a pivotal step in Organigram's global expansion strategy as a leader in the rapidly expanding cannabis industry," said James Yamanaka, chief executive officer of Organigram. "This transformational acquisition will bring together two market leaders, extend our commercial footprint into Europe and strengthen our competitive edge in the world's largest federally legal cannabis markets."

Sanity Group overview

Berlin-based Sanity Group, founded in 2018, is one of Europe's most prominent and respected cannabis companies. Sanity Group has established a reputation for leadership across several key market segments, including medical cannabis, recreational pilot programs and well-being products. Sanity Group is led by co-founder and chief executive officer Finn Age Hansel, supported by a seasoned executive management team.

The team brings expertise in entrepreneurship, operational efficiency, scaling operations, logistics and brand development.

Sanity Group's portfolio of leading brands reflects a strong commitment to excellence and innovation, securing its position at the forefront of growth within the rapidly expanding European cannabis sector.

Sanity Group's primary operations are centred in Germany, which is recognized as one of Europe's fastest-growing medical cannabis markets. This growth is fuelled by increased adoption among physicians, broader patient access and a favourable regulatory landscape following the 2024 cannabis law reform. The German medical cannabis market was valued at over two billion euros in 2025, serving approximately 800,000 patients. The market is forecast to surpass 4.5 billion euros by 2028 expecting a 50-per-cent year-over-year growth rate, with the patient population expected to reach around 1.8 million (approximately 2.0 per cent of the population), bringing it on par with other major global medical markets, such as Israel (1.9 per cent) and Australia (2.3 per cent).

Sanity Group highlights

• Year-over-year net revenue growth, from nine million euros in calendar 2023 to 19 million euros in 2024 to 60 million euros in 2025, including 19 million euros generated in the last quarter of calendar 2025. Two thousand twenty-six year-to-date results show a continued growth trend.
• Gross margin improvement, from 15 per cent in 2023 to 35 per cent in 2024 to 47 per cent in 2025.
• Estimated No. 2 market share position as of January, 2026, up from No. 5 in January, 2025.
• Strategically expanding European footprint beyond Germany and Switzerland including Poland, the United Kingdom and Czechia.
• Currently operates two locations in Swiss pilot program, with growing study participant numbers.
• Deep European regulatory expertise and network, critical to navigating markets, regulatory frameworks and intelligence as the market expands.

"I am truly excited to embark on this new chapter as our company joins forces with Organigram. Sanity's strong focus in Europe is highly complementary to Organigram's strengths, and I have tremendous confidence in their vision and ambitious business plan to scale internationally. Together, we are poised to unlock significant growth opportunities, especially as new European markets open to both medical and recreational cannabis programs. Organigram has already proven to be an exceptional partner, bringing deep expertise in areas such as cultivation, manufacturing, R&D, and innovation. These strengths will be vital as we collectively shape the rapidly expanding global cannabis landscape," said Finn Age Hansel, chief executive officer of Sanity Group.

Strategic rationale for the acquisition

"Organigram's proven track record in executing highly strategic and complementary M&A is exemplified by our proposed acquisition of Sanity Group -- a transaction that is both strategically significant and financially accretive. By combining our strengths as focused cannabis pure play companies, we will be well positioned to deliver meaningful value for our shareholders and accelerate growth in key European markets. We are truly excited about the opportunities ahead with this acquisition as we are now poised to set a new standard in the global cannabis sector together," said Paolo De Luca, chief strategy officer at Organigram.

Acquisition highlights:

1. Financially accretive acquisition that is expected to bring scale and positively impact both revenue and profitability. Sanity generated positive EBITDA (earnings before interest, taxes, depreciation and amortization) in 2025.
2. Cements Organigram's position as a leader in the growing global cannabis market. Organigram is currently No. 1 in the Canadian adult use recreational market, and on closing will become a top company in the rapidly growing German medical cannabis market, the second-largest federally legal cannabis market in the world after Canada.
3. Provides Organigram with a vertically integrated European hub and footprint. Will add local leadership, a strong network of strategic partners throughout the value chain across Europe as well as commercial, operational, medical and regulatory expertise.
4. Sanity Group operates Europe's first two legal cannabis specialty stores as part of scientific pilot projects in Switzerland. Pilot project experience also enhances credibility for future pilot projects, including in Germany.
5. Provides Organigram the opportunity to bring its industry leading brands and IP to new markets globally. The combination of both teams, with the support of the product development collaboration (PDC) generated IP, is expected to deliver a suite of next generation cannabis innovations, backed by science, to European medical markets.

Deal valuation, structuring of consideration and earnout

Sanity completed 2025 with net revenue of 19 million euros for the last quarter which, at a 130-million-euro upfront valuation, results in a last quarter annualized (LQA) multiple of 1.7 times. Based on Sanity and Germany's historic growth rate and Euromonitor's forecast of the Germany market doubling by 2028, Organigram expects net revenue to average approximately 25 million euros for the last three calendar quarters of 2026. Based on tightening competitive pressures in the German market initial expectations of gross margins of approximately 39 per cent to 40 per cent and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margins of 10 per cent to 12 per cent are targeted.

The earnout consideration will be calculated using a notional Sanity valuation, which will be arrived at by weighing net revenue and EBITDA each by 50 per cent after multiplying them by 1.75 and 12.5 times, respectively, for the 12-month period following closing. The notional Sanity valuation will be capped at 250 million euros inclusive of Organigram's interests. The earnout consideration will be calculated as the Sanity valuation less the upfront valuation, adjusted for Organigram's interests, and will have a maximum payout to the vendors of 113.8 million euros.

Earnout consideration will be settled with a maximum of 20 million euros cash and the remainder in Organigram shares issued at the 20-day VWAP on the TSX subject to a $3.00 floor and $4.00 cap.

As a condition precedent for any earnout consideration to be paid, Sanity must generate a minimum amount of EBITDA during the earnout period so that Sanity is self-sustaining from a cash flow perspective before consideration of working capital needs. Organigram will make up to 10 million euros available to Sanity on closing of the acquisition to finance working capital needs in a high-growth environment. To the extent that any of the 10 million euros is not repaid by the end of the earnout period, the earnout consideration will be reduced by the outstanding amount.

Sources of cash

Cash consideration to Sanity shareholders will be financed through a combination of cash on hand (restricted Jupiter funds), the private placement investment, and the proceeds of a credit facility with ATB Financial and a syndicate of lenders, in respect of which the company has entered into an underwritten commitment, subject to customary closing conditions.

British American Tobacco PLC (BAT) through its wholly owned subsidiary, BT DE Investments Inc., is a shareholder in both Organigram and Sanity, and has opted to take Organigram share consideration in lieu of cash for its interest in Sanity.

Private placement and top-up rights

Organigram is in advanced negotiations with BAT in respect of a $65.2-million investment to be used to finance the cash component of the acquisition and for transaction expenses. The private placement investment is expected to comprise an exercise by BAT of certain existing top-up rights and a private placement for Organigram shares.

ATB Financial senior secured credit facilities

ATB Financial, who is acting as sole lead arranger and bookrunner, provided a fully underwritten commitment of the senior secured credit facilities of up to $60-million. ATB will also act as administrative agent for the loan facilities.

The loan facilities include:

1. $40-million senior secured facility comprising a $10-million operating line and a $30-million revolving credit facility;
2. $20-million senior secured non-revolving credit facility.

The loan facilities will be available on closing, subject to customary closing conditions and bear interest at ATB's referenced benchmark rates plus a spread determined by funded debt to trailing-12-month adjusted EBITDA. The loan facilities are subject to normal course funded debt and fixed charge covenants.

Transaction summary and shareholder approval requirements

Pursuant to the purchase agreement, Organigram will indirectly acquire of all the issued and outstanding shares of Sanity Group not currently owned by Organigram. Total upfront consideration is 113.4 million euros ($183.7-million), consisting of 80 million euros ($129.6-million) in cash and 33.4 million euros ($54.1-million) in Organigram shares. In addition, the vendors will be entitled to receive the earnout consideration. The upfront consideration shares will be priced at $3.00 per Organigram share, a 71-per-cent premium to the $1.75 closing price on the TSX on Feb. 17, 2026, and the earnout consideration shares shall be priced at the TSX 20-day VWAP on the trading day prior to settlement subject to a $3.00 floor and $4.00 cap.

Organigram anticipates that the acquisition, together with the private placement investment and the credit facility (each of which is or will be conditional upon completion of the acquisition), will close concurrently in the second quarter of 2026. Completion of the acquisition is subject to certain closing conditions, including, among other things, receipt of all required regulatory approvals, including approval of the TSX and clearance under Germany's foreign direct investment regime from the German Federal Ministry for Economic Affairs and Energy, and other customary closing conditions for a transaction of this nature. Organigram's obligation to complete the acquisition is subject to the additional conditions, including approval of the acquisition by Organigram's shareholders and the arrangement by Organigram, on terms and conditions satisfactory to it, of third party financing, in an amount sufficient to pay the cash portion of the purchase price payable under the purchase agreement, which is expected to be satisfied by the closing of the private placement investment and credit facilities.

The company is required to obtain disinterested shareholder approval (50.1 per cent of shares voting at the meeting, excluding any shares held by BAT) for the acquisition under Subsections 611(c) and 604(a)(ii) of the TSX Company Manual, as the total number of shares to be issued as part of the upfront consideration and pursuant to the private placement investment (i) will exceed 25 per cent of Organigram's current shares outstanding, and (ii) will result in the value of consideration issued to BAT, an insider of the company, exceeding 10 per cent of the company's market capitalization.

In addition to the above, the acquisition and the private placement Investment will constitute related party transactions under Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions and will require majority of the minority approval under MI 61-101, being approval by a simple majority of votes cast by the shareholders of Organigram, excluding any votes attached to the shares held by BAT.

The company intends to obtain the requisite shareholder approval at its annual and special shareholders' meeting to be held on March 30, 2026.

private placement investment details

Pursuant to the private placement investment, BAT is expected to subscribe for 14,027,074 Organigram shares at a price of $3.00 per share, for gross proceeds of $42.08-million, the proceeds of which will be used to finance the acquisition, and to also exercise certain top-up rights to subscribe for 9,897,356 Organigram shares at a price of $2.335854 per share, for gross proceeds of $23.12-million.

The closing of the private placement investment is expected to be subject to the closing of the acquisition, as well as the receipt of certain regulatory approvals, approval from Organigram's shareholders and other customary conditions for a transaction of this nature.

To the extent BAT's ownership of shares in the company exceeds 30.0 per cent of the total issued and outstanding common shares of the company on a postissuance basis, BAT would, in lieu of common shares, be issued non-voting Class A convertible preferred shares of Organigram. Based on Organigram's current 135,132,782 common shares outstanding, BAT would be issued 2,353,379 common shares and 21,571,051 preferred shares pursuant to the private placement investment. The preferred shares would be eligible for conversion into voting common shares in accordance with their terms, provided that such conversion would not result in BAT's voting interest in the company exceeding 30 per cent.

Board of directors approval and opinion received

BMO Capital Markets has provided an oral opinion to the investment committee of the board and the board to the effect that, as of the date of such opinion, and subject to the assumptions, limitations and qualifications to be set forth in its written opinion, the consideration to be paid by the company pursuant to the purchase agreement is fair, from a financial point of view, to the company.

After considering the opinion and the advice of its financial and legal advisers, among other factors, the board has unanimously determined that the acquisition and the credit facility are in the best interests of Organigram with BAT's nominees to the board declaring an interest in such matters thereby abstaining from the vote.

Additional information regarding the acquisition and private placement investment

Copies of the purchase agreement and the definitive agreement governing the private placement investment and a material change report containing additional information regarding the acquisition and the private placement investment will be filed on Organigram's SEDAR+ profile, and filed or furnished to the Securities and Exchange Commission on EDGAR. This press release is only a summary of certain principal terms of the acquisition and is qualified in its entirety by reference to the more detailed information contained in the material change report.

Advisors and counsel

In connection with the acquisition, Organigram engaged EY for financial and tax advisory work, BMO Capital Markets to provide the fairness opinion, Hogan Lovells LLP as its local legal counsel in Germany, and Goodmans LLP as its Canadian legal counsel. Sanity Group engaged its former managing director and chief investment and strategy officer Max Narr for the management of the acquisition and Rothschild as its exclusive financial adviser. Katharina Erbe (RSR) and Patrick Biagosch (Biagosch Partner) acted as its legal counsel in Germany and McMillan LLP as its legal counsel in Canada. BAT engaged Stikeman Elliott LLP as its legal counsel in Canada in connection with the private placement investment.

Investor presentation

About Organigram Global Inc.

Organigram Global is a Nasdaq Global Select Market- and TSX-listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project Ltd., Organigram Global participates in the United States and Canadian cannabinoid beverage markets. Organigram is focused on producing high-quality cannabis for adult consumers, as well as developing international business partnerships to extend the company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Collective Project, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, N.B., and Lac Superieur, Que., with a dedicated edibles manufacturing facility in Winnipeg, Man. The company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 (carbon dioxide) and hydrocarbon extraction capabilities, and is optimized for formulation refinement, postprocessing of minor cannabinoids, and preroll production. The facility in London will be optimized for labelling, packaging and national fulfilment. The company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).

About Sanity Group GmbH

Sanity Group aims to improve people's quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on cannabinoid-based pharmaceuticals and consumer goods. To harness the full potential of cannabis, Sanity Group invests in research of the cannabis plant and its active ingredients as well as in specific areas of application. Sanity Group, co-founded in Berlin in 2018 by Finn Age Hansel, includes Vayamed, avaay Medical and ZOIKS (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), vaay (lifestyle), and Grashaus Projects (recreational cannabis Swiss pilot project). Near Frankfurt am Main, Sanity Group also operates a logistics and production facility for cannabis pharmaceuticals.

We seek Safe Harbor.